The FDA has issued a statement warning that doses of Botox received by over 350 medical centers in the U.S. may have been produced outside of the country. In an official statement, the agency points to a firm called Canada Drugs that may have supplied non-FDA approved drugs.
"Medical practices that purchase and administer illegal and unapproved medications from foreign sources are placing patients at risk and potentially depriving them of proper treatment," the FDA said in a December 19 statement.
This is not, however, the FDA's first brush with Canada Drugs. Earlier this year the agency warned as many as 19 medical centers that doses of the cancer drug Avastin may have been counterfeit. Another three warnings later followed about the same drug. All of these are brands readily distributed through Canada Drug.
For comments and feedback contact: editorial@rttnews.com
Health News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.